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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.025In nondiabetic rat models of renal disease, angiotensin II (Ang II) perpetuates podocyte injury and
promotes progression to end-stage kidney disease. Herein, we wanted to explore the role of Ang II in
diabetic nephropathy by a translational approach spanning from in vitro to in vivo rat and human studies,
and to dissect the intracellular pathways involved. In isolated perfused rat kidneys and in cultured human
podocytes, Ang II down-regulated nephrin expression via Notch1 activation and nuclear translocation of
Snail. Hairy enhancer of split-1 was a Notch1-downstream gene effector that activated Snail in cultured
podocytes. In vitro changes of the Snail/nephrin axis were similar to those in renal biopsy specimens of
Zucker diabetic fatty rats and patients with advanced diabetic nephropathy, and were normalized by
pharmacological inhibition of the renin-angiotensin system. Collectively, the present studies provide
evidence that Ang II plays a relevant role in perpetuating glomerular injury in experimental and human
diabetic nephropathy via persistent activation of Notch1 and Snail signaling in podocytes, eventually
resulting in down-regulation of nephrin expression, the integrity of which is crucial for the glomerular
ﬁltration barrier. (Am J Pathol 2013, 183: 119e130; http://dx.doi.org/10.1016/j.ajpath.2013.03.025)Supported by the European Community’s Seventh Framework Pro-
gramme grant 241544 (SysKid) and a Fondazione Aiuti per la Ricerca sulle
Malattie Rare fellowship (Bergamo, Italy) (P.R.).
E.G. and N.P. contributed equally to this work.During the past 25 years, the burden of diabetes mellitus has
almost doubled worldwide, and projection for the future is
alarming.1 The increasing diabetes prevalence will also
inevitably result in increasing proportions of deaths from
cardiovascular disease2 and increased prevalence and asso-
ciated consequences of other complications, such as
nephropathy, a major cause of illness in diabetes.3 The
nature and amount of glomerular capillary protein traf-
ﬁcking and resulting proteinuria are prognostic markers for
cardiovascular and renal outcomes.
As documented in animal models of streptozotocin-
induced diabetes,4 the enhanced intraglomerular capillary
pressure is the initiating early event of glomerular damage
and proteinuria in this disease. Ficoll clearance studies in
diabetic rats found that enhanced intraglomerular capillary
pressure stretched glomerular walls, which further led to
direct glomerular cell injury and impaired the selective
function of the glomerular capillary, an effect explained
by the appearance of large pores that exceed the sizes ob-
served in normal conditions and allowed increased ﬁltra-
tion of plasma proteins.5,6 Mechanical strain also increasesstigative Pathology.
.angiotensin II (Ang II) production and the expression of
angiotensin type 1 receptors in podocytes7 that line the outer
aspect of the glomerular capillary barrier in vivo,8,9 poten-
tially contributing to further sustaining the glomerular
hypertension-induced damage in diabetes. However, there is
also evidence that, independent of its hemodynamic effect,
Ang II may directly impair the glomerular barrier-sieving
function, possibly through inhibition of nephrin expres-
sion,10,11 the essential protein component of the glomerular
slit diaphragm, an elaborate multiprotein network bridging
adjacent podocyte foot processes.10,12 This observation has
been conﬁrmed in previous studies in diabetic animals
showing that blockade of Ang II synthesis/activity preserved
in the glomeruli the expression of nephrin and prevented overt
proteinuria.6,13 Thus, in diabetes, a pathogenetic relationship
between Ang II and early proteinuria via functional podocyte
Gagliardini et alalteration throughmodulation of nephrin protein level has been
suggested. Nevertheless, whether Ang II would contribute to
establish persistent podocyte dysfunction after the initial cell
injury induced by glomerular hypertension, eventually allow-
ing disease progression in diabetic kidneys, remains ill deﬁned.
This possibility is supported by recent studies in nondiabetic rat
models of progressive renal disease showing that Ang II is
essential to perpetuate podocyte injury and promote progres-
sion to end-stage kidney disease.14
Moreover, the molecular signaling pathways by which
Ang II down-regulates the nephrin level in the podocytes in
diabetes are unknown. Evidence is available that the
expression of the intracellular domain of Notch1, a family of
transmembrane receptors that mediate transcription of target
genes,15 is increased in podocytes of diabetic mice.16,17
Because Notch1 operates by controlling the expression of
the transcription factor, Snail,18 which has been shown to
repress nephrin expression in rodent podocytes,19 we
hypothesize that the Notch1/Snail pathway could be a key
intracellular signal coupling Ang II to nephrin in diabetes.
In the studies reported herein, we addressed these ques-
tions and showed consistently in in vitro cell culture, in vivo
rat model of diabetic nephropathy, and in patients with type
2 diabetes that Ang II induced persistent down-regulation of
nephrin expression in podocytes via Notch1/Snail signals.
Taken together, our data implicate an important role for the
Ang II Notch1/Snail axis in the pathogenesis of diabetic
nephropathy.
Materials and Methods
Cell Culture and Experimental Design
Conditionally immortalized human podocytes were grown
and differentiated as previously described.20 Podocytes were
maintained for 24 hours in serum-free conditions and then
incubated with medium or with 100 nmol/L Ang II (Calbio-
chem,La Jolla, CA) at different time intervals.Nephrin protein
expression andmRNA transcript levels were evaluated inAng
IIetreated podocytes after 3 hours by immunoﬂuorescence
and real-time RT-PCR, respectively. g-Secretase inhibitor
(GSI) X (1 mmol; Calbiochem), was added to the cells 1 hour
before and during the incubationwithAng II. The intracellular
domain of Notch1 (ICN1) and Snail nuclear translocation
were assessed by immunoﬂuorescence analysis at different
time intervals. In additional experiments, Snail mRNA and
protein expression levels were evaluated in podocytes trans-
fectedwith control nontarget small-interfering RNA (siNULL)
or siRNA speciﬁc for hairy enhancer of split-1 (siHES1).
Quantitative Real-Time PCR
Total RNA was isolated from human podocytes by TRIzol
Reagent (Invitrogen, Life Technologies Italia, Monza, Italy),
according to the manufacturer’s instruction. Contaminating
genomicDNAwas removed byRNase-freeDNase (Promega,120Ingelheim, Germany) for 1 hour at 37C. Puriﬁed RNA (2 mg)
was reverse transcribed using 50 ng of random hexamers
and 50U of SuperScript II Reverse Transcriptase (Invitrogen)
for 1 hour at 42C. No enzyme was added for reverse
transcriptase negative controls.
Ampliﬁcation was performed on a 7300 Real Time PCR
System with SYBR Green PCR Master Mix (Applied Bio-
systems, Life Technologies, Monza, Italia), according to the
manufacturer’s protocol. The following primers were used:
300 nmol/L human NEPHRIN forward 50-CGTCTTGCT-
GAGGGCATCTC-30 and reverse 50-TGACTCGGTCCTC-
TTCCGAC-30; 300 nmol/L human SNAIL forward 50-TG-
CCCTG-CGTCTGCGGAACC-30 and reverse 50-GGGCT-
TCTCGCCAGTGTGGG-30; 300 nmol/L human HES1
forward 50-AGCACAGAAAGTCATCAAAGCC-30 and re-
verse 50-AT-GCCGCGAGCTATCTTTCT-30; and 50 nmol/L
18S forward 50-ACGGCTACCACATCCAAGGA-30 and
reverse 50-CGGGAGTGGGGTAATTTGCG-30. The DDCT
technique was used to calculate cDNA content in each sample
using the cDNA expression in human podocyte control as
calibrator.
Immunoﬂuorescence Analysis on Cultured Cells
Podocytes were ﬁxed in 2% paraformaldehyde (Electron
Microscopy Science, Hatﬁeld, PA) and 4% sucrose (Sigma-
Aldrich, Milan, Italy) and then permeabilized with 0.3%
Triton X-100 (Sigma-Aldrich). After blocking the non-
speciﬁc binding sites, cells were incubated with rabbit poly-
clonal anti-nephrin antibody (1:200; Abcam, Cambridge,
UK), rabbit polyclonal antieNotch1-cleaved Val1744 anti-
body (1:200; Abcam) that detects endogenous levels of
fragment of activated Notch1 (ICN1), or a rabbit polyclonal
anti-Snail antibody (1:200; Abcam). After washing in PBS,
cells were incubated with a goat anti-rabbit CY3-conjugated
secondary antibody (Jackson ImmunoResearch Laboratories,
West Grove, PA) and then counterstained with DAPI (Sigma-
Aldrich). Coverslips were mounted using Dako Fluorescence
Mounting Medium (Dako Corporation, Carpentaria, CA).
Samples were examined under confocal inverted laser
microscopy (LSM 510 Meta; Zeiss, Jena, Germany). Quanti-
ﬁcation of ICN1 or Snail-positive nuclei per total number of
cell nuclei, identiﬁed by DAPI staining, was assessed in 15
random ﬁelds per sample (nZ 3 experiments).
Silencing of the HES1 Gene
Podocytes were transfected with 30 pmol Silencer Select
predesigned siRNA speciﬁc for the HES1 sequence,
NM_005524.3 (s6920, 5 nmol; Ambion, Life Technologies
Italia, Monza, Italy), or with control nontarget siRNA
(Silencer Select Negative Control 2 siRNA; Ambion) using
the Amaxa Human NHDF Nucleofector Kit (VPE-1001;
Lonza, Basel, Switzerland), according to the manufacturer’s
protocol. HES1 expression was evaluated 48 hours after
transfection.ajp.amjpathol.org - The American Journal of Pathology
Angiotensin II in Diabetic NephropathyIsolated Perfused Rat Kidney Model
Isolated kidneys from adult male Sprague-Dawley rats
(Charles River Laboratories Italia S.r.l., Calco, Italy) were
perfused in a recirculating system at a constant pressure of 100
mmHg with an artiﬁcial cell-free medium, as previously
described.21 Each kidney was allowed 15 to 20 minutes to
equilibrate after beginning the perfusion. A 10-minute baseline
urine collection and a perfusate samplewere obtained at the end
of the clearance period. Then, 16ng/minuteAng II or vehicle (n
Z 4 for each group) was infused into the renal artery for 10
minutes, and bothurine and perfusate sampleswere collected at
the end of the clearance for creatinine assay. Urinary protein
concentration and glomerular ﬁltration rate were evaluated.
The infusion time andAng II concentration were chosen on the
basis of a previous study showing that, after 10 minutes of
infusion of 16 ng/minute Ang II, the urinary protein excretion
rate was already signiﬁcantly increased in respect to baseline
values and preceded the decline of glomerular ﬁltration rate.22
At the end of perfusion, kidney specimens were collected
and processed for immunoﬂuorescence evaluation.
In Vivo Study in Diabetic Rats
Two-month-old male Zucker diabetic fatty (ZDF) rats (ZDF/
Gmi-fa/fa) and aged-matched nondiabetic lean rats (ZDF/
Gmi-fa/þ; Charles River Laboratories Italia S.r.l., Calco,
Italy), were kept on a 12-hour light/dark cycle with free access
to water. ZDF rats were maintained on Purina 5008 rat chow
(protein, 26.8 kcal%; carbohydrate, 56.4 kcal%; and fat, 16.7
kcal%) to accelerate onset of diabetes. At 4 months, ZDF rats
were randomized to receive the following daily, until month
8: vehicle (water, nZ 3); and 1mg/kg ramipril in the drinking
water (nZ 4). Four lean rats were used as controls. Systolic
blood pressure was measured by tail plethysmography.
Urinary protein excretion was measured by the Coomassie
Blue method using a Cobas Mira plus autoanalyzer (Roche
Diagnostic System, Basel, Switzerland). At the end of the
study, the removed kidneys were ﬁxed in Duboscq-Brazil and
embedded in parafﬁn. Sections (3 mm thick; Ultrotome V,
LKB, Bromma, Sweden) were stained with H&E and PAS
reagents. At least 100 glomeruli were examined for each
animal. The extent of glomerular damage was expressed as
percentage of sclerotic glomeruli. Tubular changes (atrophy,
casts, and dilation) were graded from 0 to 4 (0, no changes; 1,
changes affecting <25% of the sample; 2, changes affecting
25% to 50% of the sample; 3, changes affecting >50% to
75%of the sample; and 4, changes affecting>75% to 100%
of the sample). Renal biopsy specimens were simultaneously
processed and analyzed by the same pathologist (E.G.), who
was unaware of the nature of the experimental groups.
Animal Care
Animal care and treatment were conducted according to
institutional guidelines in compliance with national (DecretoThe American Journal of Pathology - ajp.amjpathol.orgLegislativo number 116, Gazzetta Ufﬁciale supplement 40,
18 Febbraio 1992, Circolare number 8, Gazzetta Ufﬁciale
14 Luglio 1994) and international (European Economic
Community Council Directive 86/609, OJL358-1, December
1987; Guide for the Care and Use of Laboratory Animals,
US National Research Council, 1996) laws and policies.
Animal studies were submitted to and approved by the
Institutional Animal Care and Use Committee ofMario Negri
Institute (Milan, Italy).
Patient Enrollment
Nineteen subjects with a known history of type 2 diabetes
mellitus, diagnosed according to the criteria of the World
Health Organization, were enrolled in the study. Eight
patients not receiving any renin-angiotensin system blocking
drugs as part of their anti-hypertensive therapy and 11 patients
treated with the angiotensin-converting enzyme (ACE) inhib-
itor, ramipril (treatment started at 2.5 mg/day and then up
titrated to 5, 10, and 15mg/day according to renal function and
tolerability), from at least 1 month, were studied. The pre-
deﬁned inclusion criteriawere as follows: renal tissues obtained
from biopsy specimens of the patients who were admitted for
diagnostic reasons to the Nephrology Unit (Azienda Ospeda-
liera Papa Giovanni XXIII, Bergamo, Italy) (serum creatinine,
<4mg/dL; proteinuria,>0.5 g/24 hours), for at least 6months;
histological diagnosis of diabetic glomerulopathywithout other
concomitant glomerular disease; and no evidence of renovas-
cular disease, obstructive uropathy, systemic disease, and other
possibly confounding conditions. Five age- and sex-matched
non-proteinuric nondiabetic controls undergoing nephrectomy
for kidney adenocarcinoma, with proteinuria <0.5 g/24 hours
and without histological evidence of glomerular disease, were
also included. Written informed consent was obtained from all
of the patients enrolled in the study.
Morphometric Analysis at Transmission Electron
Microscopy
Renal specimens were ﬁxed with 2.5% glutaraldehyde in 0.1
mol/L cacodylate buffer (pH 7.4) for 4 hours at 4C, washed
in cacodylate buffer, and then post-ﬁxed with a solution of
tannic acideglutaraldehyde (1% tannic acid and 1% glutar-
aldehyde in 0.1 mol/L phosphate buffer, pH 7.4) for 2 hours
to increase the contrast and deﬁnition of extracellular struc-
tures in the glomerulus and reveal the isoporous substructure
of the slit diaphragm.23 Kidney fragments were then pro-
cessed, and ultrastructural evaluations were performed by
transmission electron microscopy (Morgagni 268D; Philips,
Brno, Czech Republic). An average of 50 images of three
glomeruli per animal was digitized (ﬁnal magniﬁcation,
56,000) and processed with image-processing software
(NIH Image, version 1.6; NIH, Bethesda, MD). For each
image, the length of the glomerular basement membrane was
calculated using a computer-assisted morphometric unit, as
previously described.23 Epithelial ﬁltration slit frequency121
Gagliardini et alwas evaluated as number of slits observed/micrometer of
glomerular basement membrane length. The presence of the
ﬁlamentous structure in the slits observed in each animal was
evaluated and expressed as a percentage.
Podocyte Count
Podocytes were identiﬁed using the antibody directed against
WT1, the podocyte-speciﬁc marker.13 All glomeruli included
in each biopsy specimen (from 3 to 15) were acquired by
confocal laser-scanning microscope (LSM 510 Meta) and
examined by an observer (P.R.) unaware of the identity of
samples. The estimation of the average number of podocytes
per glomerulus was determined by using morphometric
analysis proposed by Weibel,24 as previously reported.25
Immunohistochemical Analysis on Renal Tissues
Acetone-ﬁxed cryosections were subjected to antigen retrieval
and incubated with goat anti-rat/human nephrin (1:100; Santa
Cruz Biotechnology Inc., Santa Cruz, CA), rabbit anti-rat/
human Snail (1:200; Abcam), rabbit or mouse anti-rat/human
WT1 (1:50; Santa Cruz Biotechnology Inc.), and rabbit poly-
clonal to Notch1-cleaved Val1744 antibody (1:50; Abcam),
followed by the speciﬁc ﬂuorescein isothiocyanatee or Cy3-
conjugated secondary antibodies. Cell nuclei were labeled by
DAPI, and the glomerular tuft was labeled by wheat germ
agglutinin. Fluorescencewas examinedbyan inverted confocal
laser-scanning microscope (LSM 510 Meta). For nephrin and
Snail immunoﬂuorescence, the signal intensity was graded on
a scale of 0 to 3 (nephrin expression: 0, no staining; 1, highly
fragmented; 2, fragmented; and 3, linear signal; Snail expres-
sion: 0, no staining; 1, spotted; 2,weak; and3, strongdiffusion).
Duboscq-Brazil ﬁxed and parafﬁn-embedded human kidney
sections (3 mm thick) were used. After antigen retrieval, the
sections were incubated with the primary antibodies to Notch1-
cleaved Val1744, human zonula occludens protein (ZO)-1
(1:25; Zymed Laboratories, San Francisco, CA), and human
CD2AP (1:100; Santa Cruz Biotechnology Inc.). Then, speci-
mens were incubated with the biotinylated species-speciﬁc
secondary antibodies, avidin-biotin peroxidase complex solu-
tion, and developed with diaminobenzidine. Slides were
counterstained with hematoxylin and observed using light
microscopy. Seven glomeruli, on average, in each sample were
analyzed by an investigator (P.R.) unaware of biopsy groups.
For each glomerulus, Notch1 activation was expressed as
percentage of ICN1-positive cell nuclei per total number of cell
nuclei identiﬁed in a hematoxylin-stained kidney section.
Negative controls were obtained by omitting the primary anti-
body on adjacent sections. All renal tissue sections were ana-
lyzed by the same pathologist (P.R.), in a single-blindedmanner.
Statistical Analysis
Results are reported as means  SEM. Statistical compari-
sons were analyzed by the nonparametric Kruskal-Wallis122test for multiple comparisons or analysis of variance with
Bonferroni correction or Student’s t-test for unpaired data.
Linear regression analysis was performed between immu-
nohistochemistry scores for nephrin and degree of protein-
uria. P < 0.05 was considered signiﬁcant. In the correlation
analysis, a Spearman r correlation coefﬁcient was used.
Results
Ang II Affects Glomerular Filtration Function and
Structure in Isolated Perfused Rat Kidneys by Lowering
Nephrin
The role of Ang II in progressive disruption of glomerular
perm-selectivity to macromolecules is well established in
ex vivo models, in which Ang II enhances ﬁltration of
molecules with radii 34 Å and increases protein excre-
tion.21,22 To investigate whether Ang II induces proteinuria
by direct modulation of glomerular nephrin expression and
eventually podocyte foot process injury, we used an ex vivo
model of isolated perfused rat kidney.21 The reasoning
behind this approach is that, with this tool, hemodynamic
modiﬁcations can be minimized by artiﬁcially maintaining a
constant renal perfusion pressure of 100 mmHg throughout
the experiment; thus, changes in glomerular capillary
permeability are more likely to correspond to a direct effect of
Ang II on the capillary wall function. Ang II was infused
during 10 minutes into the renal artery of the isolated kidney
preparation. A group of kidneys infused with vehicle was
taken for comparison. Consistent with our previous
reports,21,22 Ang II signiﬁcantly increased urinary protein
excretion compared with baseline values (32.4  4.1 versus
11.7  1.6 mg/minute; P < 0.01) (Figure 1A). At variance,
vehicle infusion did not change the protein excretion rate
(13.4  1.9 mg/minute) that was comparable to that found at
baseline (Figure 1A). No signiﬁcant change in glomerular
ﬁltration rate was observed after Ang II (baseline, 0.93 
0.10 mL/minute; post-Ang II, 0.90  0.10 mL/minute) or
vehicle (baseline, 0.89  0.10 mL/minute; post-vehicle,
0.84  0.10 mL/minute).
The increase of proteinuria after the short-term Ang II
infusion was associated with modiﬁcations in the compo-
nents of the glomerular capillary barrier and in the podocyte
structure. After Ang II, the immunoﬂuorescence signal for
the slit diaphragm protein, nephrin, was markedly altered in
50% of glomeruli examined, exhibiting a heterogeneous
expression with a punctuate pattern or loss of protein at focal
areas within glomeruli (Figure 1B). In glomeruli of vehicle-
infused kidneys, the immunoﬂuorescence signal for nephrin
was unaffected, with a typical predominant linear pattern
along the peripheral capillary loops (Figure 1B). The Ang
IIeinduced changes in nephrin localization were associated
with ultrastructural evidence of podocyte damage. Trans-
mission electron microscopy analysis showed mild Ang
IIeinduced foot process effacement (frequency of ﬁltration
slit pores, 2.36  0.1 slits/mm glomerular basementajp.amjpathol.org - The American Journal of Pathology
Figure 1 Infusion of Ang II in rat isolated perfused kidneys affects
glomerular barrier function and integrity. A: Proteinuria levels at baseline
(white bars) and after a 10-minute infusion with 16 ng/minute Ang II or
vehicle (grey bars). *P < 0.01 versus baseline. B: Representative images of
nephrin immunoﬂuorescence (red) in glomeruli of rats after Ang II (left
panel) or vehicle (rightpanel) infusion.C: Transmission electronmicrographs
of the capillary wall ultrastructure of rats infused with Ang II (left panel) or
vehicle (right panel). Arrowhead, podocyte effacement; arrows, podocyte
slits with or without the linear diaphragm between neighboring podocytes.
Angiotensin II in Diabetic Nephropathymembrane versus 2.74  0.2 slits/mm after vehicle infusion)
(Figure 1C). In noneffaced regions, the percentage of intact
pores spanned by the linear image of slit diaphragm was
signiﬁcantly lower in Ang IIe than in vehicle-infused
kidneys (57.3%  6.4% versus 79.3%  3.5%; P < 0.05)
(Figure 1C).Ang II Down-Regulates Nephrin Expression via
Activation of the Notch1-Snail Signaling Pathway in
Human Cultured Podocytes
To elucidate the intracellular molecular mechanism linking
Ang II to nephrin down-regulation, we focused on Notch1
and its downstream effector, Snail, a negative regulator of
nephrin expression in podocytes. In untreated cells,
nephrin immunostaining showed a punctuated pattern, with
peripheral distribution that was markedly reduced afterThe American Journal of Pathology - ajp.amjpathol.org3 hours’ exposure to Ang II (Figure 2A). Similarly,
nephrin mRNA expression in Ang IIetreated podocytes
was signiﬁcantly lower than in control untreated podocytes
(P < 0.01) (Figure 2B). The role of Notch1 in Ang
IIeinduced down-regulation of nephrin was assessed in
podocytes treated with the g-secretase inhibitor, GSI X,
which blocks the proteolytic activation of Notch1.17 As
shown in Figure 2B, the addition of GSI X to the cell
culture medium blunted the lowering effect of Ang II on
nephrin mRNA expression, although it was unable to
completely restore the mRNA expression to normal levels
(Figure 2B), suggesting the involvement of Notch1
signaling in Ang IIepromoted down-regulation of nephrin
mRNA in podocytes.
Because activation of Notch1 results from the cleavage of
the transmembrane domain at Val 1744, with the release of
ICN1 that translocates into the nucleus, we analyzed the
presence of ICN1 nuclear staining in Ang IIetreated
podocytes at different time intervals. In control cells, ICN1
weakly localized in the cytoplasm (Figure 2C). Ang II
increased ICN1 expression and promoted protein trans-
location from the cytoplasm to the nucleus, with a peak at
30 minutes (Figure 2C). Nuclear ICN1 staining in response
to Ang II persisted over time until 120 minutes, an effect
that was conﬁrmed by quantiﬁcation of the percentage of
ICN1-positive nuclei (Figure 2C). Transforming growth
factor-b, herein used as a positive control, markedly
increased the activation and nuclear translocation of ICN1,
similar to Ang II (Figure 2C).
We next examined the involvement of activated Notch1 in
the Snail signaling pathway in cultured podocytes. Immuno-
ﬂuorescence experiments showed that Snail protein localized
in the cytoplasm of untreated podocytes (Figure 3A). Ang II
induced Snail protein expression and translocation into the
nucleus, starting from 30 minutes, reaching a peak at 60
minutes (Figure 3A). The g-secretase inhibitor, GSI X,
markedly reduced the enhanced Snail protein nuclear trans-
location in response to Ang II (Figure 3A). Consistently, GSI
X normalized Snail gene expression in Ang IIetreated podo-
cytes (Figure 3B).
To explore the intracellular pathway by which Notch1
activates Snail, we focused on HES1, a downstream target
gene of Notch1 described to up-regulate Snail transcription
in other cell systems.18 Ang II signiﬁcantly increased HES1
mRNA expression after a 30-minute incubation in respect to
unstimulated cells (1.5  0.03 versus 1  0.02; nZ 3; P <
0.001). The functional role of HES1 was evaluated by
knocking down its expression with speciﬁc siRNA in
podocytes. The percentage of HES1 silencing was 80% in
respect to cells transfected with siNULL. Silencing of HES1
prevented the up-regulation of Snail mRNA in Ang IIe
treated podocytes (Figure 3B). Consistently, nuclear stain-
ing of Snail in siHES1 podocytes exposed to Ang II was
markedly reduced at 30 and 60 minutes compared with the
strong Snail activation in siNULL podocytes (Figure 3C).
This difference was also documented by the quantiﬁcation123
Figure 2 Ang II reduces nephrin expression through the involvement of Notch1 in cultured human podocytes. A: Representative images of nephrin
staining in human podocytes exposed for 3 hours to 100 nmol/L Ang II. B: Nephrin mRNA expression in human podocytes exposed to Ang II alone or in
combination with 1 mmol/L g-secretase inhibitor, GSI X. *P < 0.01 versus control podocytes; yP < 0.01 versus Ang II alone. C, top panel: Representative
images of ICN1 staining (red) and cell nuclei (DAPI, blue). Bottom panel: Quantiﬁcation of the percentage of nuclei positive for ICN1 at different time
intervals. Transforming growth factor (TGF)-b (5 ng/mL for 120 minutes) was used as a positive control. **P < 0.001 versus control podocytes.
Gagliardini et alof the percentage of Snail-positive nuclei in both siHES1- or
siNULL-transfected podocytes (Figure 3C).
Ang II Inhibition Reduces Proteinuria and Increases
Glomerular Nephrin Expression via Snail Modulation in
Rats with Diabetic Nephropathy
Based on our in vitro ﬁndings, we hypothesized that the
regulation of Notch1/Snail axis by Ang II occurred in vivo,
contributing to perpetuate podocyte injury and nephropathy
in diabetic rats. To test this hypothesis, we characterized the
renal effect of Ang II synthesis inhibition with the ACE
inhibitor, ramipril, in ZDF rats, a model that recapitulates
human type 2 diabetes.26,27 Moreover, to closely mimic the
human conditions, the diabetic animals were randomized to
treatment with ramipril or vehicle at 4 months of age when
overt nephropathy is already established. At baseline, in
diabetic rats, systolic blood pressure averaged 132.7  2.6
mmHg, and increased to 143.7  4.3 mmHg at the end of
follow-up. At 8 months, a signiﬁcant (P < 0.05) reduction
of systolic blood pressure was found in ramipril (121  3.1
mmHg) compared with vehicle-treated rats.
As shown in Figure 4A, the urinary protein excretion rate
at baseline was signiﬁcantly (P < 0.01) higher in vehicle-
treated diabetic rats than in controls, and further increased
thereafter. On the contrary, in diabetic rats, ramipril stabi-
lized proteinuria at baseline values; thus, at the age of 8
months, urinary protein excretion was similar to values
measured before treatment, with a signiﬁcant reduction with
respect to the vehicle-treated group (P < 0.01) (Figure 4A).
The increase of proteinuria in vehicle-treated diabetic rats124paralleled the worsening of renal histological features, as for
the presence of sclerotic glomeruli (score, 20.7%  2.0%)
and tubular damage (score, 1.0  0.1), lesions not detectable
in controls (sclerotic glomeruli score, 0%; tubular damage
score, 0; P < 0.01) (Figure 4B). Ramipril reduced glo-
merulosclerosis and tubular lesions to a signiﬁcant extent
(sclerotic glomeruli score, 8.3%  2.8%; tubular damage
score, 0.5  0.1; P < 0.05 versus vehicle-treated animals)
(Figure 4B).
Consistent with changes in the glomerular perm-
selectivity, diabetic rats given vehicle showed a signiﬁcant
(P < 0.05) reduction of nephrin protein expression by
immunoﬂuorescence on frozen kidney sections (score, 1.30
0.2) (Figure 4C) compared with controls (score, 2.3  0.1)
(Figure 4C). In contrast, ramipril treatment increased the
expression of nephrin in the glomeruli of diabetic animals
(score, 1.8  0.1) (Figure 4C), but the levels of protein were
lower than in nondiabetic controls.
Based on in vitro ﬁndings, the contribution of Snail in
Ang IIeinduced changes in nephrin expression was inves-
tigated in diabetic rats. Snail expression was negligible
(score, 0.7  0.1) (Figure 4C) in glomeruli of nondiabetic
controls, whereas it was signiﬁcantly increased (P < 0.01)
in the glomerular visceral epithelial layer of vehicle-treated
diabetic rats (score, 1.8  0.1) (Figure 4C). Concomitant
with the increased nephrin expression induced by ramipril,
in diabetic animals, the glomerular Snail expression was
reduced (score, 1.1  0.1) (Figure 4C). Overall, an inverse
correlation was found between Snail and nephrin protein
expression in the glomeruli that, however, did not reach
statistical signiﬁcance (r Z 0.762, P Z 0.06).ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Role of the Notch1 pathway on Snail activation in Ang
IIetreated podocytes. A: Snail protein expression in podocytes exposed
to Ang II in the presence or absence of 1 mmol/L g-secretase inhibitor,
GSI X, at different time intervals. Representative images of Snail
staining (red) and nuclei (DAPI, blue) and quantiﬁcation of Snail-
positive nuclei (%). *P < 0.001 versus control; yP < 0.001 versus
Ang II. B: Snail mRNA expression in podocytes exposed to Ang II for 1
hour in the presence or absence of GSI X and in podocytes knocked down
for HES1 with siHES1 or control nontarget siRNA (siNULL). *P < 0.001
versus control; yP < 0.001 versus Ang II or Ang II þ siNULL. C:
Representative images of Snail staining (red with DAPI in blue) in
siNULL- or siHES1-transfected podocytes exposed to Ang II at different
time intervals and relative quantiﬁcation of Snail-positive nuclei (%).
*P < 0.001 versus control; yP < 0.001 versus Ang II þ siNULL.
Angiotensin II in Diabetic NephropathyAng II Inhibition Improves Proteinuria and Restores
Nephrin via Notch1-Snail Modulation in Patients with
Diabetic Nephropathy
To examine the clinical relevance of the observation made in
diabetic ZDF rats, we next assessed whether the glomerular
nephrin/Snail axis was altered in type 2 diabetic patients with
overt nephropathy, and inhibition of Ang II synthesis with
ramipril enabled restoration of these pathways while
reducing proteinuria. To this end, proteinuria and the
glomerular expression of nephrin and Snail proteins were
assessed in diabetic patients (not given renin-angiotensin
system inhibitors/blockers, untreated diabetics), in nondia-
betic control subjects, and in a group of age- and sex-matched
diabetics given the ACE inhibitor, ramipril, for at least 1
month as part of their antihypertensive therapy. The duration
of diabetes, control of glycemia as glycosylated hemoglobin
and of blood pressure, and severity of chronic renal dys-
function were comparable in diabetic groups (Table 1). Un-
treated diabetic patients exhibited nephrotic range proteinuria
(Table 1). Ramipril signiﬁcantly reduced, but did not nor-
malize, urinary protein excretion compared with untreated
diabetic patients (Table 1).
To test whether ramipril-induced reduction of proteinuria
was associated with change in podocyte number, morpho-
metric analysis of renal biopsy specimens was performed.
The total number of podocytes per glomerulus was similarThe American Journal of Pathology - ajp.amjpathol.orgin untreated and ramipril-treated diabetic patients (533.67 
59.8 versus 557.50  68.6), and comparable to controls
(516  31.1). However, untreated diabetics showed
glomeruli with a mean volume signiﬁcantly higher than
controls (6.49  0.5  106 mm3 versus 2.72  0.2  106
mm3; P < 0.05), which translated in signiﬁcant reduction of
the volume density of podocytes (82.13  6.3 versus 190.5
 5.3  106 mm3). Moreover, to cover the increased
glomerular capillary surface, in untreated diabetic patients,
the podocytes became hypertrophic (diabetics versus
controls, 1.23  0.1 versus 0.53  0.1  104 mm3; P <
0.05). ACE inhibition did not reduce mean glomerular
volume (7.5  1.2  106 mm3) nor podocyte hypertrophy
(1.45  0.4  104 mm3); thus, the volume density of
podocytes (85.23  22.5  106 mm3) remained comparable
to that of untreated diabetics. Similarly, ramipril failed to
ameliorate renal tissue injury induced by diabetes, because
the glomerulosclerosis score was comparable in treated and
untreated patients at the histological examination (2.5  0.1
versus 2.4  0.2) (Figure 5).
Despite the absence of evident morphometric and histo-
logical changes in the glomeruli of ramipril-treated diabetic
patients, the inhibition of Ang II synthesis improved the
integrity of the glomerular capillary wall. Indeed, glomeruli
of patients given ramipril showed higher nephrin protein
expression than those of untreated diabetic patients (score, 1.4
 0.1 versus 0.7 0.2; P< 0.05) (Figure 6A). Nevertheless,125
Figure 4 Ramipril reduced proteinuria, improved renal histological
features, and restored nephrin and Snail expression in ZDF rats. A: Urinary
protein excretion rate in ZDF rats receiving vehicle or ACE inhibitor and
controls measured at 4 (pretreatment) and 8 months. *P < 0.01 versus
controls; yP < 0.01 versus untreated. B: Representative images of PAS
reagentestained kidney sections of control and diabetic animals that
received ramipril or did not receive ramipril and were sacriﬁced at 8
months. C: Photomicrographs of nephrin (red) and Snail (green) immu-
noﬂuorescence on frozen kidney sections. Nuclei were stained with DAPI.
Figure 5 Ramipril did not reduce the area of sclerosis in glomeruli of
patients with type 2 diabetes. Representative images of PAS reagente
stained kidney biopsy specimens from control and diabetic patients
untreated or treated with ramipril. Scale bars are indicated.
Gagliardini et althe nephrin signal score was still lower than in nondiabetic
controls (2.8 0.1) (Figure 6A). In a diabetic patient studied
before and after ramipril treatment, the ACE inhibition
doubled the nephrin protein expression score in glomeruli
(0.5 to 1.0), in parallel with halving the urinary protein
excretion rate (8.53 to 4.42 g/24 hours). More important,
considering the combined cohorts of diabetics and controls,
an inverse correlation was found between nephrin protein
expression and degree of proteinuria (rZ0.495,PZ 0.03),
further suggesting that aberrant regulation of nephrin in the
slit diaphragm of podocyte foot processes contributes to
changes in the ﬁltration barrier and proteinuria.Table 1 Clinical Findings of Control Subjects and Diabetic Patients at
Variable Controls (N
Age (years) 63.4  3
Male sex [no. (%)] 4 (80)
Known duration of diabetes (months) Not applic
Glycosylated hemoglobin (%) 3.2  0
Blood pressure (mmHg)
Systolic 123.7  3
Diastolic 78.4  1
Urinary protein excretion (g/day) 0.1  0
Serum creatinine (mg/dL) 1.1  0
Creatinine clearance rate (mL/minute per 1.73 m2) 91.8  1
Triglycerides (mg/dL) 127.3  9
Cholesterol (mg/dL) 156.7  1
*P < 0.01 versus controls.
yP < 0.05 versus untreated.
126In addition, the reduction of nephrin expression in the
glomeruli of diabetic patients was not the mere consequence
of reduced volume density of podocytes. Indeed, the
expression of other podocyte proteins, such as ZO-1 and
CD2AP, that are located at the cytoplasmic side of the slit
diaphragm10 was similar in untreated diabetic patients and
nondiabetic controls (ZO-1, 2.2  0.4 versus 2.8  0.1;
CD2AP, 2.2  0.3 versus 2.5  0.1) (Supplemental
Figure S1, A and B), with strong protein signals revealed
along the capillary loops, with the exception of sclerotic areas.
Consistent with our ﬁndings in ZDF diabetic rats, in dia-
betic patients, the down-regulation of nephrin expression was
associated with changes in the glomerular expression of the
transcriptional regulator, Snail. Thus, the discontinuous and
spotted signal of Snail documented in control subjects was
signiﬁcantly increased along the glomerular visceral epithe-
lial layer of untreated diabetic patients (score, 1.0  0.0
versus 2.4  0.3; P < 0.01) (Figure 6B). Double immuno-
ﬂuorescence revealed an almost complete localization of
Snail protein with the podocyte marker, WT1,13 indicating
that the transcriptional regulator localized speciﬁcally in the
podocytes (Supplemental Figure S2). Moreover, double-
immunoﬂuorescence analysis (Figure 6C) documented that
Snail expression increased in those glomeruli in which
nephrin expression was reduced (r Z 0.6, P Z 0.067),
conﬁrming the previously described role of Snail as a neph-
rin repressor.19 Inhibition of Ang II synthesis with ramiprilBiopsy
Z 5) Untreated (N Z 8) Ramipril (N Z 11)
.5 64.3  3.7 63  2.3
5 (62.5) 9 (81.8)
able 141.8  48.3 124.2  31.4
.3 6.1  0.6 6.6  0.5
.8 151.3  10.8 143.9  6.4
.6 83.8  5.3 83.1  2.6
.0 5.5  1.1* 2.2  0.5y
.0 1.82  0.4 1.7  0.2
.8 48.9  8.0 48.3  5.6
.9 199.2  50.3 179.1  18.9
3.8 227.7  22.8 229.1  15.9
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Figure 6 Ramipril restores nephrin and Snail
expression in patients with type 2 diabetes to
control levels. A: Representative images of immu-
noﬂuorescence of nephrin (red) in glomeruli of
diabetic patients, untreated or treated with ACE
inhibitor. Control subjects were included for
comparisons. B: Snail expression evaluated by
immunoﬂuorescence (green). C: Double immuno-
ﬂuorescence of nephrin and Snail. Insets, coloc-
alization of nephrin with Snail (yellow, merged
signal; twofold enlargement of boxed area).
Angiotensin II in Diabetic Nephropathysigniﬁcantly restored Snail expression signal to control levels
(score, 1.4  0.1; P < 0.01) (Figure 6, B and C).
We ﬁnally examined the podocyte expression and locali-
zation of active Notch1 in renal biopsy specimens from the
untreated and ramipril-treated diabetic patients and from
nondiabetic controls. In control subjects, a mild staining for
ICN1 was observed in few glomerular cells, and only occa-
sionally in the nuclei (Figure 7). At variance, in glomeruli of
untreated diabetic patients, ICN1 expression increased and
localized into the nuclei (Figure 7). ICN1 staining was
conﬁned to podocytes, as revealed by double immunostain-
ing with WT1, a speciﬁc marker for these glomerular
epithelial cells13 (Figure 7). Quantitative analysis of ICN1
in untreated diabetic patients showed a signiﬁcantly higherThe American Journal of Pathology - ajp.amjpathol.orgpercentage of positive nuclei than in controls (48.3% 6.4%
versus 10.3%  3.9%; P < 0.05) (Figure 7). Ramipril
reduced nuclear expression of ICN1 into the podocytes of
diabetic patients in respect to untreated ones (Figure 7).
Together, these data highlighted a key role of Notch1/Snail
signaling in the Ang IIeinduced changes in nephrin
expression, even in diabetic patients with overt nephropathy.
Discussion
Stemming from previous evidence in nondiabetic rat models
of renal disease that Ang II perpetuates podocyte injury
and promotes progression to end-stage kidney disease,14
we explored whether this possibility could apply to theFigure 7 Ramipril restores Notch1 expression in
diabetic patients. Representative images of Notch1
glomerular expression assessed by ICN1 immuno-
peroxidase. Insets, twofold enlargement of boxed
area. Arrows, mild and cytoplasmic signal in
controls that increases and becomes nuclear in
diabetic glomeruli. The staining is negative in the
absence of primary antibody (minus). Double
immunoﬂuorescence of ICN1 (green) and WT1 (red)
reveals Notch1 activation in podocytes of untreated
diabetic patients. Arrows, colocalization of the two
signals (yellow). The histogram shows the
percentage of ICN1-positive nuclei. *P < 0.05
versus control group; yP < 0.01 versus diabetic
patients.
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Figure 8 Ang II activates the Notch1/Snail signaling, which is
responsible for the pathogenesis of proteinuria in diabetic nephropathy.
Schematic drawing summarizes the molecular pathway by which Ang II,
after binding with angiotensin type 1 receptor (AT1R), induces increased
activation of Notch1. The active Notch1 (ICN1) via the downstream target
gene, HES1, increases the expression of Snail and its translocation into the
nucleus, leading to nephrin down-regulation. This series of events is
responsible for the molecular podocyte lesions and loss of the glomerular
permeability in diabetes.
Gagliardini et alprogressive renal dysfunction occurring in diabetic animals
and humans. In particular, we studied the following: i) the
Ang II contribution to persistent podocyte dysfunction, ii)
the possible involvement of nephrin based on previous data
and its relevance to perm-selective properties of the
glomerular ﬁltration barrier, and iii) the intracellular
molecular signaling coupling Ang II to nephrin. The results
of these studies form the basis of this report.
Building on our previous work,22 herein we showed that
the infusion of Ang II into the renal artery of an ex vivo
model of isolated perfused rat kidney resulted in foot
process effacement with profound rearrangement of pore
number and structure. This effect was achieved in a perfu-
sion system in which the possible confounding factor of
Ang IIeinduced increase in arterial blood pressure was
artiﬁcially minimized by maintaining constant the renal
perfusion pressure. Such structural changes were associated
with proteinuria and reduction of the glomerular expression
of nephrin, one of the major components of the slit dia-
phragm,28 as others have previously documented in the
setting of in vitro cultured podocytes.11 These data indicate
that Ang II directly promotes and is critically important for
the perturbation of the podocyte barrier. Although we
cannot exclude that other slit diaphragm proteins have
a certain role, this ex vivo model suggests that the down-
regulation of nephrin expression induced by Ang II is
essential for podocyte dysfunction.
To our knowledge, the intracellular molecular mecha-
nisms coupling Ang II to nephrin down-regulation have not
been fully unraveled. Given the relationship between
Notch1 and Snail axis18 and the pivotal role of Snail signal
in modulating nephrin gene expression,19 we elected to
investigate in cultured human podocytes these pathways and
found that Notch1/Snail signaling is actually not dispens-
able to repress nephrin gene and protein induced by Ang II.
The Notch1 signaling pathway is a short-range communi-
cation transducer that is involved in regulating many cellular
processes during development and renewal of adult tissues.15
A key step in Notch1 activation is a series of proteolytic
cleavages of Notch1 receptor by metalloprotease and g-sec-
retase that ﬁnally release the active Notch1 intracellular
domain, which travels to the nucleus.15 The g-secretase
inhibitor, GSI X, which blocks the proteolytic activation of
Notch1,17 actually blunted the Ang II effect of lowering
podocyte nephrin mRNA expression. Although in mature
kidney, little Notch1 can be detected,29 our present ﬁndings
indicate that, at least in vitro, the Notch1 pathway can be
activated in these cells under a particular setting of stimula-
tion. This is consistent with previous reports in cultured
mouse podocytes transduced with retroviral constructs
expressing the active Notch1 intracellular domain, showing
cell apoptosis induced by Notch1 activation.17 Among the
targets of Notch1 signaling, there is the transcription factor,
Snail, which is up-regulated after ICN1 recruitment into the
nucleus and subsequent activation of downstream target
genes, such as HES1.18 In keeping with these observations,128our in vitro ﬁndings demonstrate that, in human podocytes,
Ang II up-regulated the expression of the Snail gene via
Notch1 activation of the transcriptional regulator, HES1.
Collectively, these data and the ﬁnding that Ang II also
promoted Snail protein translocation to the nucleus strongly
suggest that Ang IIeinduced nephrin down-regulation in
human podocytes depends on activation of Notch1/Snail
signaling.
To assess the biological relevance of these ﬁndings,
we used an in vivo model of diabetic nephropathy in ZDF/ajp.amjpathol.org - The American Journal of Pathology
Angiotensin II in Diabetic NephropathyGmi-fa/fa rats that closely mimics human type 2 dia-
betes.26,27 Data showed that ACE inhibition with ramipril,
starting at 4 months of age when animals already had overt
nephropathy, reduced proteinuria, ameliorated glomerular
lesions, and increased the expression of nephrin protein
along the glomerular capillary wall. Relevant to the
involvement of the Notch1/Snail pathway in Ang IIein-
duced down-regulation of nephrin gene expression, in our
study, Snail protein signal was enhanced in the glomerular
visceral epithelial layer in untreated diabetic rats, in parallel
to reduction of nephrin protein. Moreover, glomerular
capillary Snail expression was reduced by ramipril, which
also normalized the nephrin level.
The translational relevance of the present study rests on
the strong similarity of Notch1/Snail signaling activation
in vitro, in diabetic rats, and in diabetic patients. Changes in
the Snail/nephrin axis induced by Ang II, comparable to
those found in rats, have also been documented herein in
patients with advanced diabetic nephropathy and overt
proteinuria. Mechanistic insight into these ﬁndings rests on
a substantial increase of Notch1 expression in podocytes of
diabetic patients, in parallel with reduction of nephrin
protein level, consistent with the results of the previously
described in vitro studies and on the demonstration that
ramipril restored the Notch1 signal to normal.
Overall, our ﬁndings offer the rationale for using therapy
that selectively targets Notch1 in diabetic nephropathy.
However, safety concerns should be accounted for long-term
treatment with g-secretase inhibitors, given the essential
physiological role of Notch1 in the hematopoietic system, the
gastrointestinal tract, and the skin.30
How Ang II activated the Notch1 pathway in diabetic
podocytes remains ill deﬁned. Ang II binds angiotensin type
1 receptors that, coupled to heterotrimetric guanine nucle-
otideebinding protein G (G proteins), activate phospholi-
pase C-b isoforms that hydrolyze phosphatidylinositol
4,5-biophosphate.31 Studies, however, have also established
complementary pathways of Ang IIemediated intracellular
signal transduction systems, such as activation of phos-
phatidylinositol 3-kinase,32,33 which stimulates the tyrosine
phosphorylation of a distinct set of cellular proteins34,35 and
leads to activation of the glycogen synthase kinase-3b; this,
in turn, regulates the Notch1 level, as shown in the 293
HEK cell line.36 Taken together, our present study led us to
propose cohesive intracellular molecular pathways of
podocyte activation in diabetes, related to the contribution
of Ang II to nephrin down-regulation (Figure 8).
In conclusion, we present evidence that, in diabetes, Ang II
plays a relevant role to perpetuate glomerular injury after the
initial insult of hyperglycemia and intraglomerular hyper-
tension, via persistent activation of Notch1 and Snail
signaling in the podocyte, eventually resulting in down-
regulation of nephrin expression, the integrity of which is
crucial for the glomerular ﬁltration barrier. The consistency of
ﬁndings in the rat model and in type 2 diabetic patients with
nephropathy provides robust insights into novel molecularThe American Journal of Pathology - ajp.amjpathol.orgmechanisms underlying progression of kidney disease in
diabetes. It also highlights the rationale for future investiga-
tions focused on strategies that modulate transduction path-
ways and foot process function to most effectively prevent
renal disease progression in diabetic patients resistant to
available treatments. This is particularly relevant considering
that, in experimental diabetes ratmodels37 and in patientswith
type 2 diabetes,38e42 blockade of the renin-angiotensin
system affords signiﬁcant renoprotection only when treat-
ment is established early in the course of kidney disease.Acknowledgments
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